A patient with refractory anemia with an excess of blasts in transformation developed pancytopenia and a concurrent interstitial pneumonia 110 days after allogeneic bone marrow transplantation. Bone marrow examination showed 0.4% giant proerythroblasts and 86.2% granulocytes, some of them large with a bizarre configuration and the others of normal size. Serum folate level was found low, 0.6 ng/ml. Immunocytochemistry with a B19-specific monoclonal antibody MAB8292 revealed B19 capsid antigen only in erythroblasts and large, bizarre granulocytes, but not in granulocytes of normal size. In situ hybridization of bone marrow cells using digoxigenin-labeled DNA probes detecting parvovirus B19 also demonstrated positive signals in 8.5% of marrow cells. Parvovirus B19 DNA was isolated from the serum and the bronchoalveolar lavage fluid of this patient by the polymerase chain reaction. These findings suggest that neutropenia may be caused by an involvement with parvovirus B19 though a deficiency of folic acid may have in part contributed to the genesis of neutropenia in the patient. The relevance of parvovirus B19 to the interstitial pneumonia remains unclear.

Keywords:
Bone marrow transplantation, Folic acid deficiency, Interstitial pneumonia, Neutropenia, Pancytopenia, Parvovirus B19
1.
Young NS: Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol 1988;25:159–172.
2.
Mortimer PP, Humphries RK, Moore JG, Purcell RH, Young NS: A human parvovirus-like virus inhibits hematopoietic colony formation in vitro. Nature 1983;302:426–429.
3.
Brown KE, Anderson SM, Young NS: Eryhtrocyte panantigen; cellular receptor for B19 parvovirus. Science 1993;262:114–117.
4.
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DAJ: Experimental parvovirus infection in humans. J Infect Dis 1985;152:257–265.
5.
Sevall JS: Detection of parvovirus B19 by dot-blot and polymerase chain reaction. Mol Cell Probes 1990;4:237–246.
6.
Jordan JA: Diagnosis of human parvovirus B19-induced anemia: correlation of bone marrow morphology with molecular diagnosis using PCR and immunocytochemistry. Cell Vision 1995;2:279–282.
7.
Cubie HA, Grzybowski J, da Silva C, Duncan L, Brown T, Smith NM: Synthetic oligonucleotide cocktails as probes for detection of human parvovirus B19. J Virol Methods 1995;53:91–102.
8.
Muir K, Todd WTA, Watson WH, Fitzsimons E: Viral-associated hemophagocytosis with parvovirus-B19-related pancytopenia. Lancet 1992;339:1139–1140.
9.
Hanada T, Koike K, Takeya T, Nagasawa T, Matsunaga Y, Takita H: Human parvovirus B19-induced transient pancytopenia in a child with hereditary spherocytosis. Br J Haematol 1988;70:113–115.
10.
McClain K, Estrov Z, Chen H, Mahoney DHJr: Chronic neutropenia of childhood: frequent association with parvovirus infection and correlation with bone marrow culture studies. Br J Haematol 1993;85:57–62.
11.
Kurtzman GJ, Ozawa K, Cohen B, Hanson G, Oseas R, Young NS: Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med 1987;317:287–294.
12.
Takahashi T, Ozawa K, Takahashi K, Asano S, Takaku F: Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation. Blood 1990;75:603–610.
13.
Srivastava A, Bruno E, Briddell R, Cooper R, Srivastava C, Besien KV, Hoffman R: Parvovirus B19-induced perturbation of human megakaryocytopoiesis in vitro. Blood 1990;76:1997–2004.
14.
Alexandersen S, Larsen S, Aasted B, Uttenthal A, Bloom ME, Hansen M: Acute interstitial pneumonia in mink kits inoculated with defined isolates of Aleutian mink disease parvovirus. Vet Pathol 1994;31:216–228.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.